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Abstract 
A novel one-dimensional coordination polymer containing -Cu(I)-Cu(II)- core with chloro bridge 
on Cu(I) and ligand bridge on Cu(II) ions (1) and a mononuclear Cu(II) complex (2) have been 
synthesized from  the reactions of  3- and 4-methoxy-3-quinolin-3-ylimino-methyl-2-phenol with 
[CuCl2(PPh3)2]. The ligands and the complexes have been characterized by spectral and 
analytical methods. In addition, the structures of both the ligands and the copper complexes were 
confirmed by single crystal X-ray diffraction studies. In both complexes, the phenolic oxygen 
and azomethine nitrogen atom of the ligand coordinate to the copper ions in a monobasic 
bidentate manner resulting in an approximately square planar geometry around the copper ion. In 
the polymeric complex, the N atom of the quinoline ring is coordinated to Cu(I) in addition to the 
phenolic oxygen and azomethine nitrogen atom coordinating to Cu(II) ion, thus bridging Cu(I) 
and Cu(II) ions in the complex. The interactions of the compounds with calf thymus DNA (CT-
DNA) have been followed by absorption and emission titration methods, which revealed that the 
compounds interact with CT-DNA through intercalation. Further, the interactions of the 
compounds with bovine serum albumin (BSA) were also investigated using UV–visible, 
fluorescence spectroscopic methods. The results indicated that complex 1 exhibited a stronger 
binding to CT-DNA and BSA than the free ligands and complex 2. In addition, the in vitro 
cytotoxicity experiment showed that complexes 1 and 2 exhibit potent cytotoxic properties 
against PANC-1and Hela cells. Moreover, while complex 1 showed prominent cytotoxic activity 
against both PANC-1 and Hela cells with IC50 of 17.91 and 11.67 µM, complex 2 showed 
  
moderate cytotoxic activities with IC50 of  25.13 and 16.41 µM in PANC-1 and Hela cells. 
Further, apoptosis was confirmed by fluorescence image using EB/AO reagent. 
Keywords: Schiff base ligands, polymer and mononuclear Cu(II) complexes, DNA/BSA 
binding, cytotoxicity.  
Introduction 
Currently, there has been an increasing interest in the study of multinuclear copper complexes 
displaying quite interesting structural, magnetic, biological and catalytic properties [1]. In this 
connection, a large variety of synthetic strategies media have been applied to build such 
multinuclear architectures with different terminal and bridging ligands [2] and ligands of  
heterocyclic compounds containing a nitrogen atom have been given a special attention here [3–
5]. As far as the area of bioinorganic chemistry research is concerned, focus has been given to 
the synthesis of new transition metal complexes possessing anticancer properties. Inorganic 
chemists concentrated on the strong interactions between the electron-rich biomolecules 
(DNA/protein) and electron-deficient metal ions in the complexes in order to ascertain the 
anticancer properties and hence, while designing new anticancer drugs, the study of the binding 
properties of metal complexes with DNA is of great significance [6]. It is also essential to find 
out the interaction of the complexes with protein since proteins in plasma have been found to 
carry several endo- and exo-genous compounds and therefore, in the process of  developing new 
drugs, studies on the interaction of metal complexes with proteins like BSA are essential [7-10]. 
In the area of finding new metal based anticancer complexes, a combination of a heterocyclic 
ring with an azomethine moiety as lignds have been shown to exhibit potential biological activity 
[11–19]. Among the transition metal ions tried in the synthesis, copper ion has shown as 
promising candidate since its positive redox potential is ideal for biological electron transfer 
reactions [20]. In this connection, copper complexes containing heterocyclic compounds have 
shown a wide range of biological and pharmaceutical activities that includes DNA binding and 
cleavage, antimicrobial, anticancer and antioxidant behavior [21-24]. Due to the presence of 
heterocycles in quinolones, metal complexes derived from quinoline derivatives have been found 
to exhibit excellent DNA/protein binding and antitumor activities [25,26]. Our interest in the 
synthesis of polymeric complexes really emerged from the previous reports on the structural and 
biological applications of the Cu(II) coordination polymers (Figure A) [27-29]. Herein, we report 
  
the synthesis, characterization and anticancer properties of a novel bridged one dimensional 
Cu(I)-Cu(II) coordination polymer complex and a mononuclear Cu(II) complex. 
                    
Figure A. Biologically active copper polymer complexes. 
EXPERIMENTAL SECTION 
Materials and method 
All the chemicals used in the study were purchased from sigma Aldrich and used without further 
purification after having been dried according to the standard procedures [30]. The ligands and 
[CuCl2(PPh3)2] were prepared according to the literature methods [31,32]. Infrared spectra of the 
ligand and the metal complexes were recorded as KBr discs over the range of 4000–400 cm−1 
using a Jasco FT-IR 4100 FT-IR spectrophotometer. The melting points were recorded with a 
Lab India Melting point apparatus and elemental analyses (CHNS) were performed on a Vario 
EL III Elementar analyser instrument. The electronic spectra of the complexes were recorded 
with a Jasco V-630 spectrophotometer and emission spectra were measured using a Jasco FP 
6600 spectrofluorometer. 1H NMR spectra were recorded on a Bruker AMX 500 NMR 
spectrometer at 500 MHz. DNA binding, viscometry, Ethidium bromide replacement, Protein 
binding and cytotoxicity experiments were carried out by strictly  following the  procedures reported 
in the literature [33-37]. 
Crystallography 
Single crystal X-ray diffraction data for the ligands L1 and L2, and complexes 1 and 2 were 
collected at 100(2) K on a Bruker APEX II diffractometer using Mo-Kα radiation (λ = 0.71073 
Å). Data collections were performed using a CCD area detector. Intensities were integrated in 
SAINT [38] and absorption corrections based on equivalent reflections were applied using 
SADABS [39]. The structures were solved using Superflip [40,41] and refined against F2 in 
SHELXL [42,43] using Olex2 [44]. All of the non-hydrogen atoms were refined anisotropically 
while all the present hydrogen atoms were located geometrically and refined using a riding 
  
model, apart from the O-H protons in L1 and L2 which were located in the difference map and 
refined freely.  In the case of complex 1, the toluene solvent included in the lattice was 
disordered over two positions; the occupancies of the fragments were determined by refining 
them against a free variable with the sum of the two sites set to equal 1, the occupancies were 
then fixed at the refined values. Restraints and constraints were applied to maintain sensible 
geometries and thermal parameters. In addition, Squeeze within Platon [45,46] was used to 
remove disordered solvent from the lattice of L1 that could not be sensibly modeled. Crystal 
structure and refinement data are given in Table 1. Crystallographic data for compounds have 
been deposited with the Cambridge Crystallographic Data Centre as supplementary publication 
CCDC 1468959, 1549578-1549580. Copies of the data can be obtained free of charge on 
application to CCDC, 12 Union Road, Cambridge CB2 1EZ, UK [fax(+44) 1223 336033, e-mail: 
deposit@ccdc.cam.ac.uk]. 
Preparation of the ligands 
3-methoxy-3-quinolin-3-ylimino-methyl-2-phenol (L1): L1 was prepared [31] using3-amino 
quinoline (1.4 g 10mmol) and 2-hydroxy 3-methoxy benzaldehyde (1.5 g 10 mmol) as shown in 
Scheme 1. On cooling the mixture, an orange precipitate was formed which was filtered off. It 
was then washed with methanol and dried under vacuum. Orange colored single crystals suitable 
for X-ray diffraction studies were obtained from slow evaporation of the compound from ethyl 
acetate/methanol solvents. Yield: 96 %. M.p.: 156 ºC. Anal. Calc. for C17H14N2O2(%): C, 73.37; 
H, 5.07; N, 10.07. Found (%): C, 73.28; H, 4.95; N, 10.02; %.  FT-IR (cm-1) with KBr disk: 3428 
(ʋOH), 1626 (ʋC=N).UV-Vis (DMSO), λmax(nm) [εmax (dm3 mol˗1 cm˗1)]:282 (78384), 331 (727414), 
402 (444100) (Intra-ligand transition). 1H NMR (300 MHz, CDCl3) δ 13.26 (s, 1H, -OH), 8.96 (d, 
J = 2.4 Hz, 1H, (HC=N)), 8.83 (s, 1H, (aromatic)), 8.16 (d, J = 8.3 Hz, 1H, (aromatic)), 8.00 (d, 
J = 2.2 Hz, 1H, (aromatic)), 7.90 (d, J = 8.0 Hz, 1H, (aromatic)), 7.74 (t, J = 7.0 Hz, 1H, 
(aromatic)), 7.61 (t, J = 7.1 Hz, 1H, (aromatic)), 7.15 – 7.03 (m, 1H, (aromatic)), 6.96 (t, J = 7.8 
Hz, 2H, (aromatic)), 3.98 (s, 3H, -OCH3). 
4-methoxy-3-quinolin-3-ylimino-methyl-2-phenol (L2): L2 was prepared using 3-amino 
quinoline (1.4 g 10mmol) and of 2-hydroxy 4-methoxy benzaldehyde (1.4 g 10 mmol). The 
yellow compound obtained was separated and yellow colored single crystals suitable for X-ray 
diffraction studies were obtained from slow evaporation of the compound from 
chloroform/methanol. Yield: 89 %. M.p.: 158 ºC. Anal. Calc. for C17H14N2O2 (%): C, 73.37; H, 
  
5.07; N, 10.07. Found (%): C, 73.29; H, 4.97; N, 10.01; %. FT-IR (cm-1) with KBr disk: 3426 
(ʋOH), 1628 (ʋC=N). UV-Vis (DMSO), λmax(nm) [εmax (dm3 mol˗1 cm˗1)]: 227 (65863), 358 (689) 
(Intra-ligand transition). 1H NMR (DMSO-d6, ppm): 13.245 (S, 1H, -OH), 9.1 (s, 1H, HC=N), 
8.32 (d, J = 2.4 Hz, 1H, (aromatic)), 8.0 – 8.05 (m, 2H, (aromatic)), 7.72 – 7.16 (m, 2H, 
(aromatic)), 7.61 – 7.66 (m, 2H, (aromatic)), 6.55 (d, J = 4 Hz, 1H, (aromatic)), 6.60 – 6.63 (m, 
1H, (aromatic)), 3.8 (s, 3H, -OCH3), 
Synthesis of the complexes 
Complex 1: An ethanolic solution 10 (cm3) of L1 (0.040 g 0.143 mmol) was slowly added to a 
solution of [CuCl2(PPh3)2] (0.100 g 0.143 mmol) dissolved in chloroform (30 cm
3) and  the 
mixture was heated under reflux for 6 h. Upon cooling, the resulting solution afforded a reddish 
brown colored precipitate which was filtered, washed with petroleum ether (60-80oC) and dried 
under vacuum before being recrystallized from hot methanol/toluene. The dark brown crystals 
obtained were suitable for X-ray diffraction. Yield: 48 %. M.p.:198 ºC. Anal. Calc. for 
C42H36ClCu2N2O2P (%): C, 68.60; H, 5.76; N, 12.00. Found (%): C, 68.57; H, 5.71; N, 11.96. 
FT-IR (cm-1) with KBr disk: 1606 (ʋC=N). UV-Vis (DMSO), λmax(nm) [εmax (dm3 mol˗1 cm˗1)]: 
225 (321679) (Intra-ligand transition), 272 (450282) (Intra-ligand transition), 400 (853267) (Ligand 
to metal charge transfer).EPR (X-band), ‘g’ value 2.04. 
Complex (2): Complex 2 was prepared using the same procedure as described for complex 1 
using L2 (0.040 g 0.143 mmol) and [CuCl2(PPh3)2] (0.100 g 0.143 mmol). Upon cooling, the 
resulting solution afforded a reddish brown colored precipitate. It was filtered, washed with 
petroleum ether (60-80 oC) and dried under vacuum and recrystallized from hot methanol/DMF. 
The dark reddish brown crystals obtained were suitable for X-ray diffraction. Yield: 47 %. 
M.p.:176 ºC. Anal. Calc. for C34H26CuN4O4 (%): C, 66.06; H, 4.24; N, 9.06. Found: C, 66.01; H, 
4.18; N, 9.02; %. FT-IR (cm-1) in KBr disk: 1593 (ʋC=N). UV-Vis (DMSO), λmax(nm) [εmax 
(dm3mol˗1 cm˗1)]:239 (959714) (Intra-ligand transition), 294 (696352) (Intra-ligand transition), 370 
(333330) (Ligand to Metal Charge Transfer (LMCT).EPR (X-band), ‘g’ value 2.1. 
Cytotoxic studies: 
Using Dulbecco’s modified Eagle medium (DMEM) containing 10 % fetal bovine serum and 
incubated in a humidified condition (5% of CO2 and 95 % of air), the PANC-1 and Hela cells 
were cultured. Then, 10×105 cells/plate were seeded in the 96-well plate and incubated with fresh 
DMEM for 24 h. The cells were washed twice with phosphate-buffered saline (PBS) and freshly 
  
prepared DMEM medium before the serially diluted test samples were added to the plate. The 
control and blanks were separated on each test plate. After 24 h of the treatment, the cells were 
washed twice with PBS and incubated with 100 μL of DMEM containing a 10 % WST-8 cell 
counting kit solution. It was then kept for 3-4 h of incubation and the absorbance was measured 
at 450 nm (PerkinElmer Enpiremultilabel reader). Cell viability was calculated by using the 
equation: Cell viability (%) = [Abs (Test sample) – Abs (Blank)/ Abs (Control) – Abs (Blank)]× 100 % 
Fluorescence Images using EB/AO reagent 
3× 105 PANC-1 and Hela cells that were used for the study have been seeded in 30 mm dishes 
and were incubated overnight in humid conditions. The cells were then washed twice with PBS 
and freshly prepared serially diluted test samples in DMEM (treated) were added. After 24 h of 
incubation, 10 μL of ethidium bromide (EB)/acridine orange (AO) reagent was added to each 
tested dishes or control and incubated for another 5 min in dark condition. Then the cell 
morphology was captured by EVOS FL cell imaging system (20 × objective) under fluorescent 
mode. 
Results and discussion  
Synthesis  
The reaction between [CuCl2(PPh3)2] and the ligands in the ratio  1:1 in ethanol/chloroform 
resulted in the formation of new complexes as shown in Scheme 1.The ligands and complex 2 
were soluble in methanol, ethanol, chloroform, dichloromethane, DMF and DMSO. Complex 1 
was soluble in DMF and DMSO.  
  
 
Scheme 1.  Preparation routes of the ligands and their Cu(II) complexes. 
Spectral characterization 
The electronic spectra of the ligands showed three strong absorption bands in the regions at 227-282, 
331-358 and 402 nm  which have been assigned to intra ligand transitions [47]. In the Cu(II) 
complexes, three bands were observed in the regions at  239-255, 272-294 and 370-400 nm. The 
high intensity bands in the regions 239-255 and 272-294 nm have been assigned to intra ligand 
transitions, while the less intense band at 370-400 nm has been assigned as ligand to metal charge 
transfer transition [48-50]. The infrared spectra of the ligands exhibited ˗OH vibration in the 
region 3426-3428 cm-1 which disappeared completely after complexation with the Cu(II) ion as a 
result of the deprotonation followed by coordination through the phenolic oxygen in both  the 
  
two complexes. An azomethine nitrogen (HC=N) band that appeared in the region 1626-1628 
cm-1 for the ligands has been shifted to lower frequency in the complexes as a result of 
coordination through the azomethine nitrogen [51]. In the 1H NMR spectra, a sharp singlet 
appeared at δ 13.24–13.26 ppm was assigned to the phenolic ˗OH group in the free ligands (1H 
NMR spectra of the ligands are shown in Figures S1and S2) which disappeared in the spectra of 
the complexes indicating the coordianation of phenolic O after deprotonation. The spectrum of 
L1 showed a doublet at δ 8.96 ppm for the azomethine proton while in L2 a singlet was observed 
at δ 9.1 ppm corresponding to the azomethine proton both of which disappeared on coordination 
to the metal ion in the complexes. However, the singlet found corresponding to the ˗OCH3 group 
at δ 3.98–3.8 ppm for the ligands L1 and L2 were seen for the complexes as well. The resonances 
due to aromatic protons in the ligands were observed in the range at δ 8.63-6.63 ppm [52,53] and 
they were present for the complexes also.  The X-band EPR of the Cu(II) complexes 1 and 2 were 
recorded at room temperature (Figure S3 and S4). Complex 1 showed well resolved quartet 
hyperfine splitting typical of square planar Cu(II) system. The observed values of g|| and g⊥ were 
2.34, 2.04 for complex 1 suggesting that the system is axial (g|| > g⊥). The value of exchange 
interaction term G > 4.0 suggested that the unpaired electron of Cu(II) ion was present in the  
dx2-y2 orbital [54]. The complex 2 showed a well resolved isotropic resonance typical of square 
planar Cu(II) system. The g value of 2 was 2.1 [55]. 
Crystallography 
The molecular structures of the ligands and complexes are shown in Figures 1-4, and the 
crystallographic data and structure refinement details are listed in Table 1. L1crystallized in the 
orthorhombicspace group Iba2 while L2 crystallized in a monoclinic crystal system with the 
space group P21/c. The azomethine, N2-C8, bond lengths of 1.288(6) Å (L1) and 1.288 (2) Å(L2) 
and the O2-C2 bond length of 1.348(6) Å (L1) and 1.350 (2) Å(L2) are indicative of the presence 
of a C=N double bond and a phenolic OH in both the ligands. Complex 1 crystallized in the 
triclinic space group P-1 as a 1D polymeric chain with two different Cu environments.  One Cu 
(II) has two L1 ligands coordinated in a bidentate fashion through the imine nitrogen (N1) and 
phenolic oxygen (O1) forming a six-member chelate rings. The Cu(II) ion adopts an 
approximately square planar geometry with unique O-Cu1-N angles of 88.85(7)° and 91.16(7)°. 
As the Cu(II) ion sits on an inversion center, it is therefore, necessarily in the same plane as the 
coordinated O and N from the two coordinated ligands. The charge on the complex was 
  
neutralized by two oxygen ions from two ligand molecules.  The quinolone nitrogen atom 
coordinated to a second Cu ion which has a distorted tetrahedral geometry with angles around 
the Cu ion ranging from 105.24(2)°–124.80(5)°.  The second Cu ion also has a PPh3 ligand 
attached and forms a double Cl bridge to a symmetry related Cu ion of the same type. Complex 2 
crystallized in the monoclinic crystal system within the P21/c space group. Two L2 coordinated 
in a bidentate manner to the Cu(II) ion through the imine nitrogen (N2) and phenolic oxygen 
(O1) forming six-member chelate rings and replacing all of the triphenylphospine ligands and 
chloride ions from the Cu(II) precursor which is rare.  Again, the Cu(II) ion sits on an inversion 
center and adopts an approximately square planar geometry with unique O-Cu1-N angles of 
89.75(5)° and 90.25(5)°. Important bond lengths and bond angles of the complexes 1 and 2 
showed in (Table S1).  
 
Figure 1. Structure of L1 with the atomic numbering scheme depicted. Thermal ellipsoids are 
depicted at the 50% probability level. 
 
 
Figure 2. Structure of L2 with the atomic numbering scheme depicted. Thermal ellipsoids are 
depicted at the 50% probability level. 
  
 
Figure 3. Structure of complex 1 with the atomic numbering scheme depicted. Thermal 
ellipsoids are depicted at the 50% probability level. Symmetry codes i = -x, 1-y, 2-z, ii = -x, 1-y, 
1-z. 
 
 
Figure 4. Structure of complex 2 with the atomic numbering scheme depicted. Thermal 
ellipsoids are depicted at the 50% probability level. Symmetry code i = 1-x, 1-y, 1-z. 
  
Table 1. Crystal data and structure refinement data for L1, L2, complex 1 and 2. 
Identification code  L1 L2 1 2 
Empirical formula  C17H14N2O2 C17H14N2O2 C42H36ClCu1.5N2O2P  C34H26CuN4O4 
Formula weight  278.30  278.30  762.46  618.13  
Temperature/K  100(2)  100(2)  100(2)  100(2)  
Crystal system  orthorhombic  monoclinic  triclinic  monoclinic  
Space group  Iba2  P21/c P-1  P21/c 
a/Å  16.6220(13)  15.8477(9)  9.4952(2)  15.0224(5)  
b/Å  30.172(3)  5.6667(3)  13.6296(3)  7.1743(2)  
c/Å  6.2568(5)  15.5148(8)  14.2121(3)  12.9204(4)  
α/°  90  90  84.202(2)  90  
β/°  90  109.409(4)  76.260(2)  105.408(2)  
γ/°  90  90  80.165(2)  90  
Volume/Å3 3137.9(4)  1314.11(13)  1756.87(7)  1342.45(7)  
Z  8  4  2  2  
ρcalcg/cm3 1.178  1.407  1.441  1.529  
μ/mm-1 0.079  0.094  1.078  0.863  
F(000)  1168.0  584.0  787.0  638.0  
Crystal size/mm3 0.40 × 0.24 × 0.16  0.34 × 0.18 × 0.10  0.43 × 0.29 × 0.12  0.35 × 0.33 × 0.10  
Radiation  MoKα (λ = 0.71073)  MoKα (λ = 0.71073)  MoKα (λ = 0.71073)  MoKα (λ = 0.71073)  
2θ range for data 
collection/°  
4.902 to 52.744  2.724 to 55.826  4.104 to 55.922  2.812 to 55.966  
Index ranges  
-20 ≤ h ≤ 20,  
-37 ≤ k ≤ 36,  
-7 ≤ l ≤ 7  
-20 ≤ h ≤ 20,  
-6 ≤ k ≤ 7,  
-20 ≤ l ≤ 20  
-12 ≤ h ≤ 12,  
-17 ≤ k ≤ 15,  
-18 ≤ l ≤ 18  
-19 ≤ h ≤ 19,  
-9 ≤ k ≤ 9,  
-11 ≤ l ≤ 17  
Reflections collected  12314  11483  31217  12021  
Rint / Rsigma 0.0807 / 0.0759  0.0658 / 0.0661  0.0492 / 0.0498  0.0307 / 0.0289  
Data/restraints/ 
parameters  
3205/1/195  3149/0/195  8379/230/490  3235/0/197  
Goodness-of-fit on 
F2 
0.994  1.010  1.026  1.035  
Final R indexes 
[I>=2σ (I)]  
R1 = 0.0613,  
wR2 = 0.1324  
R1 = 0.0482,  
wR2 = 0.1029  
R1 = 0.0373,  
wR2 = 0.0820  
R1 = 0.0297,  
wR2 = 0.0716  
Final R indexes [all 
data]  
R1 = 0.1126,  
wR2 = 0.1567  
R1 = 0.0985,  
wR2 = 0.1243  
R1 = 0.0599,  
wR2 = 0.0899  
R1 = 0.0373,  
wR2 = 0.0751  
Largest diff. 
peak/hole / e Å-3 
0.23/-0.23  0.26/-0.27  0.48/-0.53  0.37/-0.32  
 
 
DNA binding studies 
Before estimating the antitumor activities of any new compound, the interaction between DNA 
and the newly synthesized compounds need to be examined and one of the most common ways 
  
to investigate such interaction is to use the electronic absorption spectroscopy [56,57]. Hence, we 
measured the absorption spectra using a constant concentration (10 µM) of the synthesized new 
compounds with increasing concentrations of CT-DNA (0-100 µM) (Figure 5). The following 
spectral changes were observed on the incremental additions of DNA to the test compounds. The 
absorption bands (intra-ligand transitions) of the ligands L1 and L2 exhibited a hyperchromism 
with approximately a 4 and 5 nm wavelength shifts respectively. The absorption spectrum of 
complex 1 which consists of three resolved bands (intra ligand and ligand to metal charge 
transitions) showed a hyperchromism with a wavelength shift of 3 nm as the DNA concentration 
was increased. In the case of complex 2, hyperchromism with a wavelength shift of 5 nm was 
observed on the addition of DNA. In addition to the above change, complex 2 showed an isosbestic 
point appearing at 293 nm suggesting that a chemical equilibrium exists between the DNA and 
complex 2. These results indicate that the compounds bind to DNA via intercalation. In order to 
to compare the binding strengths of the compounds, their intrinsic binding constants (Kb) with 
CT-DNA were determined from the following equation. 
[DNA]/[εa-εf] = [DNA] / [εb-εf] + 1/Kb[ εb-εf] 
where [DNA] is the concentration of DNA in base pairs, εais the extinction coefficient of the 
compound at a given DNA concentration, εf is the extinction coefficient of the complex in free 
solution and εb is the extinction coefficient of the complex when completely bound to DNA.  
A plot of [DNA]/(εa-εf) versus [DNA] gave a slope and an intercept equivalent to 1/[εa-εf] and 
1/Kb[εb-εf] respectively. The intrinsic binding constant Kb obtained for L1, L2, 1 and 2 are  0.5873 × 
105, 0.5042× 105, 1.3494 × 105 and 0.8743 × 105 M-1 respectively which have been obtained from the 
ratio of the slope to the  intercept in the plots of [DNA] ( Figure 6). From the binding constant values, 
it is observed that complex 1 exhibited a better binding than complex 2 and the free ligands withCT-
DNA, possibly due to intercalative mode [58]. These results indicate that the complex 1 penetrates 
more deeply into and stacks more strongly with the base pairs of the DNA than the other 
compounds tested.  
 
 
  
 
 
Figure 5. Electronic titration of the L1 (A), L2(B), complex 1 (C) and complex 2 (D).Arrow shows 
that the absorption intensities increase upon increasing DNA concentration. 
 
  
 
Figure 6. Plot of [DNA]/(εa-εf) versus [DNA] for the compounds. 
Ethidium bromide (EB) replacement studies. 
After having found the binding ability of compounds with DNA, some other studies are 
necessary to confirm the binding mode and the binding affinity and this is often done by 
ethidium bromide replacement investigations. Ethidium bromide (EB) is a planar cationic dye 
which can be used as a sensitive fluorescence probe for native DNA. Usually, EB emits an 
intense fluorescent light in the presence of DNA due to its intercalation between the adjacent 
DNA base pairs [59,60] which can be used indirectly as a proof  to find out the DNA binding 
mode. There will be a decrease in fluorescence of EB as and when EB is replaced from DNA by 
a quencher, usually the compound under investigation and the consequent quenching is due to 
the reduction in the number of binding sites on the DNA that are still available to the EB. Hence, 
we carried out the emission spectra of the DNA-EB system with increasing concentrations of the 
ligands and the complexes and the results are shown in Figure 7. One can observe from the 
figure that there is a decrease in the fluorescence intensity due to the displacement of EB 
molecules from their DNA binding sites by the replacement by both the ligands and complexes 
[61].The extent of quenching of the compounds can be estimated qualitatively by employing 
Stern-Volmer equation:  
I0/I = 1 + Kq[Q]. 
Here, I0 and I are the fluorescence intensities in the absence and presence of the compounds, Kq 
is a linear Stern–Volmer quenching constant, and [Q] is the total concentration of a compounds 
  
to that of DNA. The Stern-Volmer plot is given in Figure 8 and the values of Kq have been 
obtained from the ratio of the slope to the intercept in the plot of I0/Iversus [Q]. The values 
obtained for the ligands and complexes are 2.90 × 103,5.16 × 103, 4.04 × 103 and 5.22 × 103 M-1 
and these values indicate that the interaction of all of the compounds with DNA is likely to be 
through intercalation [62]. 
 
 
Figure 7. Emission titration of the DNA-EB system in the presence of compounds L1 (A), L2(B), 
complex 1 (C) and complex 2 (D). 
 
 
  
 
Figure 8. Stern-Volmer plot of the fluorescence titration for the compounds. 
Viscosity experiment 
In addition to the experiments carried out so far to find out the binding mode, viscosity 
measurements need to be carried out to confirm the mode of binding of the compounds [63]. 
Hence, we carried out the viscosity measurements in order to find out the relative change in  
viscosity of DNA in the presence of increasing amounts of complexes 1 and 2  which suggested 
that the viscosity of DNA increases on the addition of 1and 2 (Figure 9). In general, the viscosity 
of DNA increases steadily when compounds intercalate between adjacent DNA base pairs, and 
hence,  these results indicate that complexes 1 and 2 bind to CT-DNA by the intercalation mode 
and also that the complex 2 binds to CT-DNA more strongly than complex 1. 
  
 
 
Figure 9. Viscosity of the complexes on the adding of CT-DNA. 
Protein binding studies 
Since proteins are involved in the transport of drugs through the bloodstream, it is also important 
to find out how the compounds interact with protein in order to assess their ability to function as 
a drug. Thus, it is essential to understand the protein–compound interaction and hence, binding 
experiments with BSA were carried out using the newly synthesized ligands and complexes 
through fluorescence spectral studies. The fluorescence spectra were recorded in the range of 290-
450 nm upon excitation at 342 nm by adding various concentrations of the compounds (0-50 µM) to 
the solution of BSA (1 µM). The recorded fluorescence emission spectra of BSA are given in Figure 
10. It is found from the spectra that there is hypochromicity with a blue shift for all the four 
compounds studied indicating that all the compounds bind to the BSA protein [64]. Further, 
fluorescence quenching data has also been examined with the Stern-Volmer equation and Scatchard 
equation. If the binding of compounds with BSA takes place at equilibrium, the equilibrium binding 
constant can be examined according to the Scatchard equation.  
log[I0-I/I ] = log Kbin+ n log[ Q] 
  
where Kbin is the binding constant of the compoundsthrough BSA and n is the number of binding 
sites. One can calculate the binding constant (Kbin) and the number of binding sites (n) from the plot 
of log[F0-F/F] versus log[Q] (Figure 11). Moreover, from the plot of I0/I versus [Q], the quenching 
constant (Kq) have also been calculated (Figure 12). The calculated Kq, Kbin, and n values are listed in 
Table 2. The calculated value of n is nearly 1 for all of the compounds, indicating the presence of just 
a single binding site in BSA for all of the compounds [65,66] 
Table 2. Quenching constant (Kq), protein binding constant (Kbin) and number of binding sites 
(n). 
 
 
 
 
 
 
 
Compound      Kq (M
-1)       Kbin(M
-1)       n 
L1            1.17 × 102          6.41 × 103         0.59 
L2                2.96 × 103          1.89 × 102         0.76 
1               2.06 × 104          8.13 × 103        1.10 
2               3.88 × 103          2.77 × 102       0.79 
  
 
Figure 10. Fluorescence quenching curves of BSA in the absence and presence of 
compoundsL1(A), L2(B), complex 1 (C) and complex 2 (D). 
 
 
Figure 11. Scatchard plot of the compounds with BSA. 
  
 
Figure 12. Stern–Volmer plot of the compounds with BSA. 
 
In order to find out the exact nature of the interaction of the new compounds with protein, UV 
absorption spectral titrations of BSA in the presence and absence of ligands and complexes have 
been carried out and the results are shown in Figure 13. It can be seen from the spectra that there 
is a decrease in the intensity of absorptionof BSA with the addition of the test compounds 
indicating clearly that a static interaction takes place between the test compounds and BSA [67]. 
 
 
Figure 13. Absorption titrations of the compounds with BSA. 
  
Cytotoxicity properties of the compounds 
Significant information obtained from the interactions of the new compounds with both DNA 
and protein encouraged us to proceed further to investigate the in vitro cytotoxicity activity. A 
detailed study of the new compounds with PANC-1 and Hela cells were carried out with 
different concentration of synthesized compounds (L1, L2, 1 and 2) incubated for 24 h, followed 
by incubation with WST-8 cell counting kit for 24 hours and the data are presented in Figures 14 
and15. Complexes 1 and 2 showed significant cytotoxic properties against both PANC-1 and 
Hela cells when compared to the ligands. It can be seen that the Complex 1 showed potent 
activity at 11.67 µM (IC50) while complex 2 showed activity at 16.41 µM (IC50) in Hela cells. 
However, Complex 1 and 2 showed moderate activity against PANC-1 cells with IC50 of 17.91 
and 25.13 µM, respectively. 
 
 
 
Figure 14. Effect of synthesized complexes (L1, L2, 1 and 2) against PANC-1cells. Data was 
calculated by mean±S.D with three replications. Positive control- Gemcitabine >25 µM. 
  
 
 
Figure 15. Effect of synthesized complexes (L1, L2, 1 and 2) against Hela cells. Data was 
calculated by mean±S.D with three replications. Positive control- Paclitaxel 0.0014 µM. 
 
Fluorescence study for apoptosis analysis 
Finally, fluorescence imaging studies were carried out to determine the cell death mechanism of 
the compounds by using treated and untreated PANC-1 and Hela cells. The cells were incubated 
with EB/ AO for 5 min in the dark before an image was captured in EVOS FL cell imaging 
system (20 × objective). It was found that after treatment of complexes 1 and 2, there was a 
dramatic increase in the apoptosis in both PANC-1 (50 µM) and Hela (25 µM) cells when 
compared to the control cells (green color fluorescence indicates live cells while a red color 
indicates dead cells) (Figure 16).The morphological changes examined by this staining method 
suggested that the cell death mechanism was through apoptosis.  
 
  
 
 
Figure 16.  PANC-1 and Hela cells were treated with complex 1 and complex 2 and incubated at 
24 h. Treated and untreated cells were stained with EB/AO. Images were taken by the 
fluorescent modes. Live cells were stained with AO and emission was captured by a bright green 
fluorescence. Dead cells were stained with EB and emission was captured by a red fluorescence 
(EVOS FL cell imaging system-20 × objective). Merged images of treated and control cells were 
presented. 
Conclusion 
Reactions of [CuCl2(PPh3)2] with 3-methoxy-3-quinolin-3-ylimino-methyl-2-phenol and 4-
methoxy-3-quinolin-3-ylimino-methyl-2-phenol yielded an one dimensional multinuclear and 
another mononuclear copper complexes. The molecular structures of the ligands and complexes 
have been confirmed by the single crystal X-ray diffraction method. The phenolic oxygen and 
azomethine nitrogen atom of the ligand coordinated to copper ion in a monobasic bidentate 
manner with approximately square planar geometry resulting in two different types of 
complexes, a polymeric and a mononuclear.It is quite surprising and difficult to explain how the 
  
change in the position of methoxy in the ligand can lead to the formation of two types of 
complexes under a similar reaction conditions. Intercalative binding mode of the compounds 
with CT-DNAwas studied by absorption and emission titrations. Potential BSA interactions of 
the complexes were also examined by absorption and fluorescence quenching experiments, 
which indicate a strong interaction between the complexes and BSA by a static quenching 
mechanism. The in vitro cytotoxicity activities of the compounds were evaluated against PANC-
1 and Hela cancer cell lines. Complex 1 and 2 displayed significant inhibitory effect on both the 
cell lines, specifically complex 1 showed potent activity at 11.67 µM against Hela after 24 h 
treatment. Morphological changes of the cells were confirmed by fluorescence imageusing 
EB/AO reagent. The strong binding affinity and cytotoxicity properties of the complex 1 might 
be due to the greater planar area, which is attributed to the extension of the π system of the 
intercalated complex 2. These results could be used for better understanding of the biological 
interactions of novel multinuclear and mononuclear complexes. 
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